Global Chemotherapy-Induced Acral Erythema Market By Grade (Grade 1, Grade 2, Grade 3, Grade 4) By Treatment (Corticosteroid, Topical Pain Relievers, Hand Creams, Vitamin E, Non-steroidal anti-inflammatory drugs, Analgesics, Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Drug Stores) By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2023 – 2031
Industry Trends
Significant improvements in cancer prevention and therapy have been accomplished over the past 20 years. Treatment-related toxicities have gained more significance as more systemic therapy options have become available and as more patients are surviving for extended periods of time while receiving treatment. Chemo-induced acral erythema, also known as Hand-foot Syndrome (HFS) or palmar-plantar erythrodysesthesia, is characterised by swelling, redness, paraesthesia (numbness), and desquamation (skin peeling) of the palms, sole, on rare instances, the knees and elbows. After several months of treatment with chemotherapy drugs, the most common of which are gemcitabine and fluorouracil, an adverse drug reaction called acrid erythema might occur. Chemotherapy can be stopped or the dosage can be decreased to treat chemotherapy-induced acryl erythema, a condition that is dose-dependent. Symptomatic treatment with analgesics and antihistaminic drugs to decrease discomfort, and edoema is used to treat chemotherapy-induced acryl erythema. Patients on capecitabine have a 60% probability of getting HFS, according to the National Center for Biotechnology Information (NCBI). Patients using capecitabine experience hand-foot syndrome more frequently. It's also more likely in individuals who receive 5-FU through a pump over time, as opposed to all at once in what's called a "bolus" dose. While the medications indicated above can be used to treat many different malignancies, hand-foot syndrome is more common in people with particular types of disease, notably gastrointestinal cancers. The clinical and financial burden brought on by the increased incidence of malignancies is significant. Treatment of adverse drug reactions (ADRs) during cancer treatment directly effects patient compliance, and hence can have a critical influence on the outcome of anticancer treatment. As a result, it's critical to identify adverse drug responses to anticancer medications as soon as possible and take preventative measures to address them. Following alopecia and mucositis, HFS is the most prevalent adverse dermatologic reaction after chemotherapy, with an incidence of 3%-64%. Doxorubicin and capecitabine have the highest incidence rates (40%–50%) and (50%–60%), respectively. The risk of HFS appears to be dose-dependent; formulations that increase the drug's concentration at the afflicted areas or prolong the serum level have the highest association rates. In terms of revenue, global chemotherapy-induced acral erythema market is growing at a CAGR of 9.7% over the forecast period (2023 – 2031). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Type Outlook
Accurately grading the severity of HFS is crucial because it informs clinical judgement when applying dose reductions, dose delays, and other forms of therapeutic treatment. The National Cancer Institute (NCI) and the World Health Organization (WHO) have classification systems that are often utilised. Whereas the NCI system uses three grades, the WHO system assigns four severity grades. A third grade system that suggests distinct grading criteria for these patients has been presented because HFS seems to manifest differently in people with skin of colour. The National Cancer Institute's criteria are used to grade hand-foot syndrome in following categories. Grade 1 skin lesions (erythema, edoema, or hyperkeratosis) are painless, whereas grade 2 skin lesions (peeling, blister, bleeding, edoema, or hyperkeratosis) are painful. At grade 3 and grade4, there are painful and significant skin changes as well as few self-care activities. NCI grade 1 toxicity is observed in around 80% of HFS patients.
Treatment Outlook
Based on treatment, the global chemotherapy-induced acral erythema market is segmented into corticosteroids, analgesics, topical pain relivers, hand creams, Vitamin E, Non-steroidal anti-inflammatory drugs and others. Corticosteriods had the highest share in the market in 2022 as these medications highly reduce the inflammation and is recommended for a systemic corticosteroid administered in a pill to help relieve the symptoms of hand-foot syndrome. Treatment for hand-foot syndrome focuses mostly on symptom management. Topical steroid creams may be provided or cancer therapy may be delayed until edoema and inflammation subside. Hand-foot syndrome is first treated by reducing the dose or stopping treatment with the chemotherapy drug that is causing it and to treat this adverse effect, the chemotherapy dose may occasionally be changed. Furthermore the use of moisturisers is advised for dryness. Medicated creams, such as urea cream, might occasionally aid in smoothing down rough skin.
Competitive Landscape
The report provides both, qualitative and quantitative research of global chemotherapy-induced acral erythema market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global chemotherapy-induced acral erythema market are
- Bausch Health Companies Inc
- Genentech, Inc.
- J&JCI
- MANUS AKTTEVA BIOPHARMA LLP
- Samex Overseas
- Sun Pharmaceutical Industries, Inc.
- Other Industry Participants
Global Chemotherapy-Induced Acral Erythema Market:
By Grade
- Grade 1
- Grade 2
- Grade 3
- Grade 4
By Treatment
- Corticosteroid
- Topical pain relievers
- Hand Creams
- Vitamin E
- Non-steroidal anti-inflammatory drugs
- Analgesics
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Drug Stores
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1.
Market
Scope
1.1.
Market
Segmentation
1.2.
Years
Considered
1.2.1.
Historic
Years: 2015 - 2021
1.2.2.
Base
Year: 2022
1.2.3.
Forecast
Years: 2023 - 2031
2.
Key
Target Audiences
3.
Research
Methodology
3.1.
Primary
Research
3.1.1.
Research
Questionnaire
3.1.2.
Global
Percentage Breakdown
3.1.3.
Primary
Interviews: Key Opinion Leaders (KOLs)
3.2.
Secondary
Research
3.2.1.
Paid
Databases
3.2.2.
Secondary
Sources
3.3.
Market
Size Estimates
3.3.1.
Top-Down
Approach
3.3.2.
Bottom-Up
Approach
3.4.
Data
Triangulation Methodology
3.5.
Research
Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Chemotherapy-Induced Acral Erythema Market
6.
Market
Synopsis: Chemotherapy-Induced Acral
Erythema Market
7.
Chemotherapy-Induced
Acral Erythema Market Analysis: Qualitative Perspective
7.1.
Introduction
7.1.1.
Product
Definition
7.1.2.
Industry
Development
7.2.
Market
Dynamics
7.2.1.
Drivers
7.2.2.
Restraints
7.2.3.
Opportunities
7.2.4.
Challenges
7.3.
Trends
in Chemotherapy-Induced Acral Erythema Market
7.4.
Market
Determinants Radar Chart
7.5.
Macro-Economic
and Micro-Economic Indicators: Chemotherapy-Induced Acral Erythema Market
7.6.
Porter’s
Five Force Analysis
8.
Global
Chemotherapy-Induced Acral Erythema Market Analysis and Forecasts, 2023 - 2031
8.1.
Overview
8.1.1.
Global
Chemotherapy-Induced Acral Erythema Market Revenue (US$ Mn)
8.2.
Global
Chemotherapy-Induced Acral Erythema Market Revenue (US$ Mn) and Forecasts, By
Grade
8.2.1.
Grade 1
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.1.3.
Market
Forecast, 2023 - 2031
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2022
8.2.1.5.1.2. Market Forecast, 2023 - 2031
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2022
8.2.1.5.2.2. Market Forecast, 2023 - 2031
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2022
8.2.1.5.3.2. Market Forecast, 2023 - 2031
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2022
8.2.1.5.4.2. Market Forecast, 2023 - 2031
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2022
8.2.1.5.5.2. Market Forecast, 2023 - 2031
8.2.2.
Grade 2
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.2.3.
Market
Forecast, 2023 - 2031
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2022
8.2.2.5.1.2. Market Forecast, 2023 - 2031
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2022
8.2.2.5.2.2. Market Forecast, 2023 - 2031
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2022
8.2.2.5.3.2. Market Forecast, 2023 - 2031
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2022
8.2.2.5.4.2. Market Forecast, 2023 - 2031
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2022
8.2.2.5.5.2. Market Forecast, 2023 - 2031
8.2.3.
Grade 3
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.3.3.
Market
Forecast, 2023 - 2031
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2022
8.2.3.5.1.2. Market Forecast, 2023 - 2031
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2022
8.2.3.5.2.2. Market Forecast, 2023 - 2031
8.2.3.5.3.
Asia
Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2022
8.2.3.5.3.2. Market Forecast, 2023 - 2031
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2022
8.2.3.5.4.2. Market Forecast, 2023 - 2031
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2022
8.2.3.5.5.2. Market Forecast, 2023 - 2031
8.2.4.
Grade 4
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2022
8.2.4.3.
Market
Forecast, 2023 - 2031
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2022
8.2.4.5.1.2. Market Forecast, 2023 - 2031
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2022
8.2.4.5.2.2. Market Forecast, 2023 - 2031
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2022
8.2.4.5.3.2. Market Forecast, 2023 - 2031
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2022
8.2.4.5.4.2. Market Forecast, 2023 - 2031
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2022
8.2.4.5.5.2. Market Forecast, 2023 - 2031
8.3.
Key
Segment for Channeling Investments
8.3.1.
By Grade
9.
Global
Chemotherapy-Induced Acral Erythema Market Analysis and Forecasts, 2023 - 2031
9.1.
Overview
9.2.
Global
Chemotherapy-Induced Acral Erythema Market Revenue (US$ Mn) and Forecasts, By
Treatment
9.2.1.
Corticosteroid
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.1.3.
Market
Forecast, 2023 - 2031
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2022
9.2.1.5.1.2. Market Forecast, 2023 - 2031
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2022
9.2.1.5.2.2. Market Forecast, 2023 - 2031
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2022
9.2.1.5.3.2. Market Forecast, 2023 - 2031
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2022
9.2.1.5.4.2. Market Forecast, 2023 - 2031
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2022
9.2.1.5.5.2. Market Forecast, 2023 - 2031
9.2.2.
Topical
pain relievers
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.2.3.
Market
Forecast, 2023 - 2031
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2022
9.2.2.5.1.2. Market Forecast, 2023 - 2031
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2022
9.2.2.5.2.2. Market Forecast, 2023 - 2031
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2022
9.2.2.5.3.2. Market Forecast, 2023 - 2031
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2022
9.2.2.5.4.2. Market Forecast, 2023 - 2031
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2022
9.2.2.5.5.2. Market Forecast, 2023 - 2031
9.2.3.
Hand
Creams
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.3.3.
Market
Forecast, 2023 - 2031
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2022
9.2.3.5.1.2. Market Forecast, 2023 - 2031
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2022
9.2.3.5.2.2. Market Forecast, 2023 - 2031
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2022
9.2.3.5.3.2. Market Forecast, 2023 - 2031
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2022
9.2.3.5.4.2. Market Forecast, 2023 - 2031
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2022
9.2.3.5.5.2. Market Forecast, 2023 - 2031
9.2.4.
Vitamin
E
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.4.3.
Market
Forecast, 2023 - 2031
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2022
9.2.4.5.1.2. Market Forecast, 2023 - 2031
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2022
9.2.4.5.2.2. Market Forecast, 2023 - 2031
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2022
9.2.4.5.3.2. Market Forecast, 2023 - 2031
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2022
9.2.4.5.4.2. Market Forecast, 2023 - 2031
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2022
9.2.4.5.5.2. Market Forecast, 2023 - 2031
9.2.5.
Non-steroidal
anti-inflammatory drugs
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.5.3.
Market
Forecast, 2023 - 2031
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1. Market Estimation, 2015 - 2022
9.2.5.5.1.2. Market Forecast, 2023 - 2031
9.2.5.5.2.
Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2022
9.2.5.5.2.2. Market Forecast, 2023 - 2031
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2022
9.2.5.5.3.2. Market Forecast, 2023 - 2031
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2022
9.2.5.5.4.2. Market Forecast, 2023 - 2031
9.2.5.5.5.
Latin
America
9.2.5.5.5.1. Market Estimation, 2015 - 2022
9.2.5.5.5.2. Market Forecast, 2023 - 2031
9.2.6.
Analgesics
9.2.6.1.
Definition
9.2.6.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.6.3.
Market
Forecast, 2023 - 2031
9.2.6.4.
Compound
Annual Growth Rate (CAGR)
9.2.6.5.
Regional
Bifurcation
9.2.6.5.1.
North
America
9.2.6.5.1.1. Market Estimation, 2015 - 2022
9.2.6.5.1.2. Market Forecast, 2023 - 2031
9.2.6.5.2.
Europe
9.2.6.5.2.1. Market Estimation, 2015 - 2022
9.2.6.5.2.2. Market Forecast, 2023 - 2031
9.2.6.5.3.
Asia
Pacific
9.2.6.5.3.1. Market Estimation, 2015 - 2022
9.2.6.5.3.2. Market Forecast, 2023 - 2031
9.2.6.5.4.
Middle
East and Africa
9.2.6.5.4.1. Market Estimation, 2015 - 2022
9.2.6.5.4.2. Market Forecast, 2023 - 2031
9.2.6.5.5.
Latin
America
9.2.6.5.5.1. Market Estimation, 2015 - 2022
9.2.6.5.5.2. Market Forecast, 2023 - 2031
9.2.7.
Others
9.2.7.1.
Definition
9.2.7.2.
Market
Estimation and Penetration, 2015 - 2022
9.2.7.3.
Market
Forecast, 2023 - 2031
9.2.7.4.
Compound
Annual Growth Rate (CAGR)
9.2.7.5.
Regional
Bifurcation
9.2.7.5.1.
North
America
9.2.7.5.1.1. Market Estimation, 2015 - 2022
9.2.7.5.1.2. Market Forecast, 2023 - 2031
9.2.7.5.2.
Europe
9.2.7.5.2.1. Market Estimation, 2015 - 2022
9.2.7.5.2.2. Market Forecast, 2023 - 2031
9.2.7.5.3.
Asia
Pacific
9.2.7.5.3.1. Market Estimation, 2015 - 2022
9.2.7.5.3.2. Market Forecast, 2023 - 2031
9.2.7.5.4.
Middle East
and Africa
9.2.7.5.4.1. Market Estimation, 2015 - 2022
9.2.7.5.4.2. Market Forecast, 2023 - 2031
9.2.7.5.5.
Latin
America
9.2.7.5.5.1. Market Estimation, 2015 - 2022
9.2.7.5.5.2. Market Forecast, 2023 - 2031
9.3.
Key
Segment for Channeling Investments
9.3.1.
By
Treatment
10. Global Chemotherapy-Induced Acral Erythema
Market Analysis and Forecasts, 2023 - 2031
10.1. Overview
10.2. Global Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
10.2.1. Hospital Pharmacies
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 -
2022
10.2.1.3. Market Forecast, 2023 - 2031
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2022
10.2.1.5.1.2. Market Forecast, 2023 - 2031
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2022
10.2.1.5.2.2. Market Forecast, 2023 - 2031
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2022
10.2.1.5.3.2. Market Forecast, 2023 - 2031
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2022
10.2.1.5.4.2. Market Forecast, 2023 - 2031
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2022
10.2.1.5.5.2. Market Forecast, 2023 - 2031
10.2.2. Retail Pharmacies
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 -
2022
10.2.2.3. Market Forecast, 2023 - 2031
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2022
10.2.2.5.1.2. Market Forecast, 2023 - 2031
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2022
10.2.2.5.2.2. Market Forecast, 2023 - 2031
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2022
10.2.2.5.3.2. Market Forecast, 2023 - 2031
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2022
10.2.2.5.4.2. Market Forecast, 2023 - 2031
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2022
10.2.2.5.5.2. Market Forecast, 2023 - 2031
10.2.3. Online Drug Stores
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 -
2022
10.2.3.3. Market Forecast, 2023 - 2031
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 - 2022
10.2.3.5.1.2. Market Forecast, 2023 - 2031
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2022
10.2.3.5.2.2. Market Forecast, 2023 - 2031
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2022
10.2.3.5.3.2. Market Forecast, 2023 - 2031
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2022
10.2.3.5.4.2. Market Forecast, 2023 - 2031
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 - 2022
10.2.3.5.5.2. Market Forecast, 2023 - 2031
10.3. Key Segment for Channeling Investments
10.3.1. By Distribution Channel
11. North America Chemotherapy-Induced Acral
Erythema Market Analysis and Forecasts, 2023 - 2031
11.1. Overview
11.1.1. North America Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn)
11.2. North America Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
11.2.1. Grade 1
11.2.2. Grade 2
11.2.3. Grade 3
11.2.4. Grade 4
11.3. North America Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
11.3.1. Corticosteroid
11.3.2. Topical pain relievers
11.3.3. Hand Creams
11.3.4. Vitamin E
11.3.5. Non-steroidal anti-inflammatory drugs
11.3.6. Analgesics
11.3.7. Others
11.4. North America Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Drug Stores
11.5. North America Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
11.5.1.1.1. Grade 1
11.5.1.1.2. Grade 2
11.5.1.1.3. Grade 3
11.5.1.1.4. Grade 4
11.5.1.2. U.S Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
11.5.1.2.1. Corticosteroid
11.5.1.2.2. Topical pain relievers
11.5.1.2.3. Hand Creams
11.5.1.2.4. Vitamin E
11.5.1.2.5. Non-steroidal anti-inflammatory drugs
11.5.1.2.6. Analgesics
11.5.1.2.7. Others
11.5.1.3. U.S Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
11.5.1.3.1. Hospital Pharmacies
11.5.1.3.2. Retail Pharmacies
11.5.1.3.3. Online Drug Stores
11.5.2. Canada
11.5.2.1. Canada Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
11.5.2.1.1. Grade 1
11.5.2.1.2. Grade 2
11.5.2.1.3. Grade 3
11.5.2.1.4. Grade 4
11.5.2.2. Canada Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
11.5.2.2.1. Corticosteroid
11.5.2.2.2. Topical pain relievers
11.5.2.2.3. Hand Creams
11.5.2.2.4. Vitamin E
11.5.2.2.5. Non-steroidal anti-inflammatory drugs
11.5.2.2.6. Analgesics
11.5.2.2.7. Others
11.5.2.3. Canada Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
11.5.2.3.1. Hospital Pharmacies
11.5.2.3.2. Retail Pharmacies
11.5.2.3.3. Online Drug Stores
11.5.3. Mexico
11.5.3.1. Mexico Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
11.5.3.1.1. Grade 1
11.5.3.1.2. Grade 2
11.5.3.1.3. Grade 3
11.5.3.1.4. Grade 4
11.5.3.2. Mexico Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
11.5.3.2.1. Corticosteroid
11.5.3.2.2. Topical pain relievers
11.5.3.2.3. Hand Creams
11.5.3.2.4. Vitamin E
11.5.3.2.5. Non-steroidal anti-inflammatory drugs
11.5.3.2.6. Analgesics
11.5.3.2.7. Others
11.5.3.3. Mexico Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
11.5.3.3.1. Hospital Pharmacies
11.5.3.3.2. Retail Pharmacies
11.5.3.3.3. Online Drug Stores
11.5.4. Rest of North America
11.5.4.1. Rest of North America Chemotherapy-Induced
Acral Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
11.5.4.1.1. Grade 1
11.5.4.1.2. Grade 2
11.5.4.1.3. Grade 3
11.5.4.1.4. Grade 4
11.5.4.2. Rest of North America Chemotherapy-Induced
Acral Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
11.5.4.2.1. Corticosteroid
11.5.4.2.2. Topical pain relievers
11.5.4.2.3. Hand Creams
11.5.4.2.4. Vitamin E
11.5.4.2.5. Non-steroidal anti-inflammatory drugs
11.5.4.2.6. Analgesics
11.5.4.2.7. Others
11.5.4.3. Rest of North America Chemotherapy-Induced
Acral Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
11.5.4.3.1. Hospital Pharmacies
11.5.4.3.2. Retail Pharmacies
11.5.4.3.3. Online Drug Stores
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Grade
11.6.3. By Treatment
11.6.4. By Distribution Channel
12. Europe Chemotherapy-Induced Acral Erythema
Market Analysis and Forecasts, 2023 - 2031
12.1. Overview
12.1.1. Europe Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn)
12.2. Europe Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
12.2.1. Grade 1
12.2.2. Grade 2
12.2.3. Grade 3
12.2.4. Grade 4
12.3. Europe Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
12.3.1. Corticosteroid
12.3.2. Topical pain relievers
12.3.3. Hand Creams
12.3.4. Vitamin E
12.3.5. Non-steroidal anti-inflammatory drugs
12.3.6. Analgesics
12.3.7. Others
12.4. Europe Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Drug Stores
12.5. Europe Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
12.5.1.1.1. Grade 1
12.5.1.1.2. Grade 2
12.5.1.1.3. Grade 3
12.5.1.1.4. Grade 4
12.5.1.2. France Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
12.5.1.2.1. Corticosteroid
12.5.1.2.2. Topical pain relievers
12.5.1.2.3. Hand Creams
12.5.1.2.4. Vitamin E
12.5.1.2.5. Non-steroidal anti-inflammatory drugs
12.5.1.2.6. Analgesics
12.5.1.2.7. Others
12.5.1.3. France Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.1.3.1. Hospital Pharmacies
12.5.1.3.2. Retail Pharmacies
12.5.1.3.3. Online Drug Stores
12.5.2. The UK
12.5.2.1. The UK Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
12.5.2.1.1. Grade 1
12.5.2.1.2. Grade 2
12.5.2.1.3. Grade 3
12.5.2.1.4. Grade 4
12.5.2.2. The UK Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
12.5.2.2.1. Corticosteroid
12.5.2.2.2. Topical pain relievers
12.5.2.2.3. Hand Creams
12.5.2.2.4. Vitamin E
12.5.2.2.5. Non-steroidal anti-inflammatory drugs
12.5.2.2.6. Analgesics
12.5.2.2.7. Others
12.5.2.3. The UK Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.2.3.1. Hospital Pharmacies
12.5.2.3.2. Retail Pharmacies
12.5.2.3.3. Online Drug Stores
12.5.3. Spain
12.5.3.1. Spain Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
12.5.3.1.1. Grade 1
12.5.3.1.2. Grade 2
12.5.3.1.3. Grade 3
12.5.3.1.4. Grade 4
12.5.3.2. Spain Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
12.5.3.2.1. Corticosteroid
12.5.3.2.2. Topical pain relievers
12.5.3.2.3. Hand Creams
12.5.3.2.4. Vitamin E
12.5.3.2.5. Non-steroidal anti-inflammatory drugs
12.5.3.2.6. Analgesics
12.5.3.2.7. Others
12.5.3.3. Spain Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.3.3.1. Hospital Pharmacies
12.5.3.3.2. Retail Pharmacies
12.5.3.3.3. Online Drug Stores
12.5.4. Germany
12.5.4.1. Germany Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
12.5.4.1.1. Grade 1
12.5.4.1.2. Grade 2
12.5.4.1.3. Grade 3
12.5.4.1.4. Grade 4
12.5.4.2. Germany Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
12.5.4.2.1. Corticosteroid
12.5.4.2.2. Topical pain relievers
12.5.4.2.3. Hand Creams
12.5.4.2.4. Vitamin E
12.5.4.2.5. Non-steroidal anti-inflammatory drugs
12.5.4.2.6. Analgesics
12.5.4.2.7. Others
12.5.4.3. Germany Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.4.3.1. Hospital Pharmacies
12.5.4.3.2. Retail Pharmacies
12.5.4.3.3. Online Drug Stores
12.5.5. Italy
12.5.5.1. Italy Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
12.5.5.1.1. Grade 1
12.5.5.1.2. Grade 2
12.5.5.1.3. Grade 3
12.5.5.1.4. Grade 4
12.5.5.2. Italy Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
12.5.5.2.1. Corticosteroid
12.5.5.2.2. Topical pain relievers
12.5.5.2.3. Hand Creams
12.5.5.2.4. Vitamin E
12.5.5.2.5. Non-steroidal anti-inflammatory drugs
12.5.5.2.6. Analgesics
12.5.5.2.7. Others
12.5.5.3. Italy Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.5.3.1. Hospital Pharmacies
12.5.5.3.2. Retail Pharmacies
12.5.5.3.3. Online Drug Stores
12.5.6. Nordic Countries
12.5.6.1. Nordic Countries Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
12.5.6.1.1. Grade 1
12.5.6.1.2. Grade 2
12.5.6.1.3. Grade 3
12.5.6.1.4. Grade 4
12.5.6.2. Nordic Countries Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
12.5.6.2.1. Corticosteroid
12.5.6.2.2. Topical pain relievers
12.5.6.2.3. Hand Creams
12.5.6.2.4. Vitamin E
12.5.6.2.5. Non-steroidal anti-inflammatory drugs
12.5.6.2.6. Analgesics
12.5.6.2.7. Others
12.5.6.3. Nordic Countries Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.6.3.1. Hospital Pharmacies
12.5.6.3.2. Retail Pharmacies
12.5.6.3.3. Online Drug Stores
12.5.6.4. Nordic Countries Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux Union
12.5.7.1. Benelux Union Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
12.5.7.1.1. Grade 1
12.5.7.1.2. Grade 2
12.5.7.1.3. Grade 3
12.5.7.1.4. Grade 4
12.5.7.2. Benelux Union Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
12.5.7.2.1. Corticosteroid
12.5.7.2.2. Topical pain relievers
12.5.7.2.3. Hand Creams
12.5.7.2.4. Vitamin E
12.5.7.2.5. Non-steroidal anti-inflammatory drugs
12.5.7.2.6. Analgesics
12.5.7.2.7. Others
12.5.7.3. Benelux Union Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.7.3.1. Hospital Pharmacies
12.5.7.3.2. Retail Pharmacies
12.5.7.3.3. Online Drug Stores
12.5.7.4. Benelux Union Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of Europe
12.5.8.1. Rest of Europe Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
12.5.8.1.1. Grade 1
12.5.8.1.2. Grade 2
12.5.8.1.3. Grade 3
12.5.8.1.4. Grade 4
12.5.8.2. Rest of Europe Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
12.5.8.2.1. Corticosteroid
12.5.8.2.2. Topical pain relievers
12.5.8.2.3. Hand Creams
12.5.8.2.4. Vitamin E
12.5.8.2.5. Non-steroidal anti-inflammatory drugs
12.5.8.2.6. Analgesics
12.5.8.2.7. Others
12.5.8.3. Rest of Europe Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.8.3.1. Hospital Pharmacies
12.5.8.3.2. Retail Pharmacies
12.5.8.3.3. Online Drug Stores
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Grade
12.6.3. By Treatment
12.6.4. By Distribution Channel
13. Asia Pacific Chemotherapy-Induced Acral
Erythema Market Analysis and Forecasts, 2023 - 2031
13.1. Overview
13.1.1. Asia Pacific Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn)
13.2. Asia Pacific Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
13.2.1. Grade 1
13.2.2. Grade 2
13.2.3. Grade 3
13.2.4. Grade 4
13.3. Asia Pacific Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
13.3.1. Corticosteroid
13.3.2. Topical pain relievers
13.3.3. Hand Creams
13.3.4. Vitamin E
13.3.5. Non-steroidal anti-inflammatory drugs
13.3.6. Analgesics
13.3.7. Others
13.4. Asia Pacific Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Drug Stores
13.5. Asia Pacific Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
13.5.1.1.1. Grade 1
13.5.1.1.2. Grade 2
13.5.1.1.3. Grade 3
13.5.1.1.4. Grade 4
13.5.1.2. China Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
13.5.1.2.1. Corticosteroid
13.5.1.2.2. Topical pain relievers
13.5.1.2.3. Hand Creams
13.5.1.2.4. Vitamin E
13.5.1.2.5. Non-steroidal anti-inflammatory drugs
13.5.1.2.6. Analgesics
13.5.1.2.7. Others
13.5.1.3. China Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.1.3.1. Hospital Pharmacies
13.5.1.3.2. Retail Pharmacies
13.5.1.3.3. Online Drug Stores
13.5.2. Japan
13.5.2.1. Japan Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
13.5.2.1.1. Grade 1
13.5.2.1.2. Grade 2
13.5.2.1.3. Grade 3
13.5.2.1.4. Grade 4
13.5.2.2. Japan Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
13.5.2.2.1. Corticosteroid
13.5.2.2.2. Topical pain relievers
13.5.2.2.3. Hand Creams
13.5.2.2.4. Vitamin E
13.5.2.2.5. Non-steroidal anti-inflammatory drugs
13.5.2.2.6. Analgesics
13.5.2.2.7. Others
13.5.2.3. Japan Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.2.3.1. Hospital Pharmacies
13.5.2.3.2. Retail Pharmacies
13.5.2.3.3. Online Drug Stores
13.5.3. India
13.5.3.1. India Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
13.5.3.1.1. Grade 1
13.5.3.1.2. Grade 2
13.5.3.1.3. Grade 3
13.5.3.1.4. Grade 4
13.5.3.2. India Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
13.5.3.2.1. Corticosteroid
13.5.3.2.2. Topical pain relievers
13.5.3.2.3. Hand Creams
13.5.3.2.4. Vitamin E
13.5.3.2.5. Non-steroidal anti-inflammatory drugs
13.5.3.2.6. Analgesics
13.5.3.2.7. Others
13.5.3.3. India Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.3.3.1. Hospital Pharmacies
13.5.3.3.2. Retail Pharmacies
13.5.3.3.3. Online Drug Stores
13.5.4. New Zealand
13.5.4.1. New Zealand Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
13.5.4.1.1. Grade 1
13.5.4.1.2. Grade 2
13.5.4.1.3. Grade 3
13.5.4.1.4. Grade 4
13.5.4.2. New Zealand Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
13.5.4.2.1. Corticosteroid
13.5.4.2.2. Topical pain relievers
13.5.4.2.3. Hand Creams
13.5.4.2.4. Vitamin E
13.5.4.2.5. Non-steroidal anti-inflammatory drugs
13.5.4.2.6. Analgesics
13.5.4.2.7. Others
13.5.4.3. New Zealand Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.4.3.1. Hospital Pharmacies
13.5.4.3.2. Retail Pharmacies
13.5.4.3.3. Online Drug Stores
13.5.5. Australia
13.5.5.1. Australia Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
13.5.5.1.1. Grade 1
13.5.5.1.2. Grade 2
13.5.5.1.3. Grade 3
13.5.5.1.4. Grade 4
13.5.5.2. Australia Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
13.5.5.2.1. Corticosteroid
13.5.5.2.2. Topical pain relievers
13.5.5.2.3. Hand Creams
13.5.5.2.4. Vitamin E
13.5.5.2.5. Non-steroidal anti-inflammatory drugs
13.5.5.2.6. Analgesics
13.5.5.2.7. Others
13.5.5.3. Australia Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.5.3.1. Hospital Pharmacies
13.5.5.3.2. Retail Pharmacies
13.5.5.3.3. Online Drug Stores
13.5.6. South Korea
13.5.6.1. South Korea Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
13.5.6.1.1. Grade 1
13.5.6.1.2. Grade 2
13.5.6.1.3. Grade 3
13.5.6.1.4. Grade 4
13.5.6.2. South Korea Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
13.5.6.2.1. Corticosteroid
13.5.6.2.2. Topical pain relievers
13.5.6.2.3. Hand Creams
13.5.6.2.4. Vitamin E
13.5.6.2.5. Non-steroidal anti-inflammatory drugs
13.5.6.2.6. Analgesics
13.5.6.2.7. Others
13.5.6.3. South Korea Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.6.3.1. Hospital Pharmacies
13.5.6.3.2. Retail Pharmacies
13.5.6.3.3. Online Drug Stores
13.5.7. Southeast Asia
13.5.7.1. Southeast Asia Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
13.5.7.1.1. Grade 1
13.5.7.1.2. Grade 2
13.5.7.1.3. Grade 3
13.5.7.1.4. Grade 4
13.5.7.2. Southeast Asia Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
13.5.7.2.1. Corticosteroid
13.5.7.2.2. Topical pain relievers
13.5.7.2.3. Hand Creams
13.5.7.2.4. Vitamin E
13.5.7.2.5. Non-steroidal anti-inflammatory drugs
13.5.7.2.6. Analgesics
13.5.7.2.7. Others
13.5.7.3. Southeast Asia Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.7.3.1. Hospital Pharmacies
13.5.7.3.2. Retail Pharmacies
13.5.7.3.3. Online Drug Stores
13.5.7.4. Southeast Asia Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1. Rest of Asia Pacific Chemotherapy-Induced
Acral Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
13.5.8.1.1. Grade 1
13.5.8.1.2. Grade 2
13.5.8.1.3. Grade 3
13.5.8.1.4. Grade 4
13.5.8.2. Rest of Asia Pacific Chemotherapy-Induced
Acral Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
13.5.8.2.1. Corticosteroid
13.5.8.2.2. Topical pain relievers
13.5.8.2.3. Hand Creams
13.5.8.2.4. Vitamin E
13.5.8.2.5. Non-steroidal anti-inflammatory drugs
13.5.8.2.6. Analgesics
13.5.8.2.7. Others
13.5.8.3. Rest of Asia Pacific Chemotherapy-Induced
Acral Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.8.3.1. Hospital Pharmacies
13.5.8.3.2. Retail Pharmacies
13.5.8.3.3. Online Drug Stores
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Grade
13.6.3. By Treatment
13.6.4. By Distribution Channel
14. Middle East and Africa Chemotherapy-Induced
Acral Erythema Market Analysis and Forecasts, 2023 - 2031
14.1. Overview
14.1.1. Middle East and Africa Chemotherapy-Induced
Acral Erythema Market Revenue (US$ Mn)
14.2. Middle East and Africa Chemotherapy-Induced
Acral Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
14.2.1. Grade 1
14.2.2. Grade 2
14.2.3. Grade 3
14.2.4. Grade 4
14.3. Middle East and Africa Chemotherapy-Induced
Acral Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
14.3.1. Corticosteroid
14.3.2. Topical pain relievers
14.3.3. Hand Creams
14.3.4. Vitamin E
14.3.5. Non-steroidal anti-inflammatory drugs
14.3.6. Analgesics
14.3.7. Others
14.4. Middle East and Africa Chemotherapy-Induced
Acral Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Drug Stores
14.5. Middle East and Africa Chemotherapy-Induced
Acral Erythema Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1. Saudi Arabia Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
14.5.1.1.1. Grade 1
14.5.1.1.2. Grade 2
14.5.1.1.3. Grade 3
14.5.1.1.4. Grade 4
14.5.1.2. Saudi Arabia Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
14.5.1.2.1. Corticosteroid
14.5.1.2.2. Topical pain relievers
14.5.1.2.3. Hand Creams
14.5.1.2.4. Vitamin E
14.5.1.2.5. Non-steroidal anti-inflammatory drugs
14.5.1.2.6. Analgesics
14.5.1.2.7. Others
14.5.1.3. Saudi Arabia Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.5.1.3.1. Hospital Pharmacies
14.5.1.3.2. Retail Pharmacies
14.5.1.3.3. Online Drug Stores
14.5.2. UAE
14.5.2.1. UAE Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
14.5.2.1.1. Grade 1
14.5.2.1.2. Grade 2
14.5.2.1.3. Grade 3
14.5.2.1.4. Grade 4
14.5.2.2. UAE Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
14.5.2.2.1. Corticosteroid
14.5.2.2.2. Topical pain relievers
14.5.2.2.3. Hand Creams
14.5.2.2.4. Vitamin E
14.5.2.2.5. Non-steroidal anti-inflammatory drugs
14.5.2.2.6. Analgesics
14.5.2.2.7. Others
14.5.2.3. UAE Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.5.2.3.1. Hospital Pharmacies
14.5.2.3.2. Retail Pharmacies
14.5.2.3.3. Online Drug Stores
14.5.3. Egypt
14.5.3.1. Egypt Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
14.5.3.1.1. Grade 1
14.5.3.1.2. Grade 2
14.5.3.1.3. Grade 3
14.5.3.1.4. Grade 4
14.5.3.2. Egypt Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
14.5.3.2.1. Corticosteroid
14.5.3.2.2. Topical pain relievers
14.5.3.2.3. Hand Creams
14.5.3.2.4. Vitamin E
14.5.3.2.5. Non-steroidal anti-inflammatory drugs
14.5.3.2.6. Analgesics
14.5.3.2.7. Others
14.5.3.3. Egypt Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.5.3.3.1. Hospital Pharmacies
14.5.3.3.2. Retail Pharmacies
14.5.3.3.3. Online Drug Stores
14.5.4. Kuwait
14.5.4.1. Kuwait Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
14.5.4.1.1. Grade 1
14.5.4.1.2. Grade 2
14.5.4.1.3. Grade 3
14.5.4.1.4. Grade 4
14.5.4.2. Kuwait Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
14.5.4.2.1. Corticosteroid
14.5.4.2.2. Topical pain relievers
14.5.4.2.3. Hand Creams
14.5.4.2.4. Vitamin E
14.5.4.2.5. Non-steroidal anti-inflammatory drugs
14.5.4.2.6. Analgesics
14.5.4.2.7. Others
14.5.4.3. Kuwait Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.5.4.3.1. Hospital Pharmacies
14.5.4.3.2. Retail Pharmacies
14.5.4.3.3. Online Drug Stores
14.5.5. South Africa
14.5.5.1. South Africa Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
14.5.5.1.1. Grade 1
14.5.5.1.2. Grade 2
14.5.5.1.3. Grade 3
14.5.5.1.4. Grade 4
14.5.5.2. South Africa Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
14.5.5.2.1. Corticosteroid
14.5.5.2.2. Topical pain relievers
14.5.5.2.3. Hand Creams
14.5.5.2.4. Vitamin E
14.5.5.2.5. Non-steroidal anti-inflammatory drugs
14.5.5.2.6. Analgesics
14.5.5.2.7. Others
14.5.5.3. South Africa Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.5.5.3.1. Hospital Pharmacies
14.5.5.3.2. Retail Pharmacies
14.5.5.3.3. Online Drug Stores
14.5.6. Rest of Middle East & Africa
14.5.6.1. Rest of Middle East & Africa
Chemotherapy-Induced Acral Erythema Market Revenue (US$ Mn) and Forecasts, By
Grade
14.5.6.1.1. Grade 1
14.5.6.1.2. Grade 2
14.5.6.1.3. Grade 3
14.5.6.1.4. Grade 4
14.5.6.2. Rest of Middle East & Africa
Chemotherapy-Induced Acral Erythema Market Revenue (US$ Mn) and Forecasts, By
Treatment
14.5.6.2.1. Corticosteroid
14.5.6.2.2. Topical pain relievers
14.5.6.2.3. Hand Creams
14.5.6.2.4. Vitamin E
14.5.6.2.5. Non-steroidal anti-inflammatory drugs
14.5.6.2.6. Analgesics
14.5.6.2.7. Others
14.5.6.3. Rest of Middle East & Africa
Chemotherapy-Induced Acral Erythema Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.5.6.3.1. Hospital Pharmacies
14.5.6.3.2. Retail Pharmacies
14.5.6.3.3. Online Drug Stores
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Grade
14.6.3. By Treatment
14.6.4. By Distribution Channel
15. Latin America Chemotherapy-Induced Acral
Erythema Market Analysis and Forecasts, 2023 - 2031
15.1. Overview
15.1.1. Latin America Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn)
15.2. Latin America Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
15.2.1. Grade 1
15.2.2. Grade 2
15.2.3. Grade 3
15.2.4. Grade 4
15.3. Latin America Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
15.3.1. Corticosteroid
15.3.2. Topical pain relievers
15.3.3. Hand Creams
15.3.4. Vitamin E
15.3.5. Non-steroidal anti-inflammatory drugs
15.3.6. Analgesics
15.3.7. Others
15.4. Latin America Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.4.1. Hospital Pharmacies
15.4.2. Retail Pharmacies
15.4.3. Online Drug Stores
15.5. Latin America Chemotherapy-Induced Acral
Erythema Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
15.5.1.1.1. Grade 1
15.5.1.1.2. Grade 2
15.5.1.1.3. Grade 3
15.5.1.1.4. Grade 4
15.5.1.2. Brazil Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
15.5.1.2.1. Corticosteroid
15.5.1.2.2. Topical pain relievers
15.5.1.2.3. Hand Creams
15.5.1.2.4. Vitamin E
15.5.1.2.5. Non-steroidal anti-inflammatory drugs
15.5.1.2.6. Analgesics
15.5.1.2.7. Others
15.5.1.3. Brazil Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.5.1.3.1. Hospital Pharmacies
15.5.1.3.2. Retail Pharmacies
15.5.1.3.3. Online Drug Stores
15.5.2. Argentina
15.5.2.1. Argentina Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Grade
15.5.2.1.1. Grade 1
15.5.2.1.2. Grade 2
15.5.2.1.3. Grade 3
15.5.2.1.4. Grade 4
15.5.2.2. Argentina Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Treatment
15.5.2.2.1. Corticosteroid
15.5.2.2.2. Topical pain relievers
15.5.2.2.3. Hand Creams
15.5.2.2.4. Vitamin E
15.5.2.2.5. Non-steroidal anti-inflammatory drugs
15.5.2.2.6. Analgesics
15.5.2.2.7. Others
15.5.2.3. Argentina Chemotherapy-Induced Acral Erythema
Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.5.2.3.1. Hospital Pharmacies
15.5.2.3.2. Retail Pharmacies
15.5.2.3.3. Online Drug Stores
15.5.3. Rest of Latin America
15.5.3.1. Rest of Latin America Chemotherapy-Induced
Acral Erythema Market Revenue (US$ Mn) and Forecasts, By Grade
15.5.3.1.1. Grade 1
15.5.3.1.2. Grade 2
15.5.3.1.3. Grade 3
15.5.3.1.4. Grade 4
15.5.3.2. Rest of Latin America Chemotherapy-Induced
Acral Erythema Market Revenue (US$ Mn) and Forecasts, By Treatment
15.5.3.2.1. Corticosteroid
15.5.3.2.2. Topical pain relievers
15.5.3.2.3. Hand Creams
15.5.3.2.4. Vitamin E
15.5.3.2.5. Non-steroidal anti-inflammatory drugs
15.5.3.2.6. Analgesics
15.5.3.2.7. Others
15.5.3.3. Rest of Latin America Chemotherapy-Induced
Acral Erythema Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.5.3.3.1. Hospital Pharmacies
15.5.3.3.2. Retail Pharmacies
15.5.3.3.3. Online Drug Stores
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Grade
15.6.3. By Treatment
15.6.4. By Distribution Channel
16. Competitive Benchmarking
16.1. Brand Benchmarking
16.2. Market Share Analysis, 2022
16.3. Global Presence and Growth Strategies
16.3.1. Mergers and Acquisitions
16.3.2. Product Launches
16.3.3. Investments Trends
16.3.4. R&D Initiatives
17. Player Profiles
17.1. Bausch Health Companies Inc
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. Genentech, Inc.
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. J&JCI
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. MANUS AKTTEVA BIOPHARMA LLP
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. Samex Overseas
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6. Sun Pharmaceutical Industries, Inc.
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7.
Business
Strategies
17.7. Other Market Participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.